Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MPL | P40238 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072859 | 1.00 | MMP13 (0.48) | MMP13MPLROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL2373894 | 0.90 | HTT (0.55) | MMP13ROCK2ROCK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2374577 | 0.90 | MPL (0.46) | MMP13MPLROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL31681851 | 0.90 | HTT (0.55) | MMP13ROCK2ROCK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24139180 | 0.89 | SMN1; SMN2 (0.53) | MMP13MPLROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL13466583 | 0.88 | ROCK2 (0.42) | MPLROCK2ROCK1SMN1; SMN2RPS6KA5 | |
| SCHEMBL2374694 | 0.87 | NPC1 (0.51) | MMP13SMN1; SMN2MAPK1GAAHPGD | |
| SCHEMBL31681834 | 0.87 | NPC1 (0.51) | MMP13SMN1; SMN2MAPK1GAAHPGD | |
| SCHEMBL12254348 | 0.87 | CYP1A2 (0.41) | MPLROCK2ROCK1SMN1; SMN2MAPK1 | |
| SCHEMBL2373405 | 0.86 | CYP1A2 (0.58) | ROCK2ROCK1SMN1; SMN2MAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103625-A1 | METHOD FOR CONSTRUCTING THYMUS ORGANOID AND USE THEREOF | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-21 | — | — | WO | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| CN-122060666-A | Lipid combination, culture medium and method for multidirectional differentiation of human induced pluripotent stem cells into three germ layers and application of lipid combination and culture medium | 上海昂朴生物科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260132380-A1 | Hepatocyte Expansion Methods | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-14 | — | — | US | claimed |
| EP-4735586-A1 | CELLULAR REPROGRAMMING | Samuel, Amy Jane (NZ) | 2026-05-06 | — | — | EP | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115318-A1 | GENE CORRECTION INDUCED NEURAL STEM CELLS USING HUNTINGTIN GENE-SPECIFIC GUIDE RNA, AND CELL THERAPEUTIC AGENT USING THE SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2026-04-30 | — | — | US | claimed |
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731754-A2 | SERUM-FREE METHODS FOR DERIVATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIAL CELLS AND RELATED CELLS, COMPOSITIONS, METHODS, AND SYSTEMS | The Regents of the University of California (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-3027737-A1 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS | F.HOFFMANN-LA ROCHE AG (CH) | 2016-06-08 | — | — | EP | claimed |
| US-20160145578-A1 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS | HOFFMANN-LA ROCHE INC. (US) | 2016-05-26 | — | — | US | claimed |
| EP-2606126-B1 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) | HOFFMANN LA ROCHE (CH) | 2016-05-18 | — | — | EP | claimed |
| CN-103068974-B | Body cell is to the conversion of the reprogrammed NSC (irNSC) of induction | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-11 | — | — | CN | claimed |
| US-9297025-B2 | Conversion of somatic cells to induced reprogrammed neural stem cells (irNSCs) | HOFFMANN-LA ROCHE INC. (US) | 2016-03-29 | — | — | US | claimed |
| WO-2015041606-A1 | CORNEAL STROMAL KERATOCYTE CULTURE | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-03-26 | — | — | WO | claimed |
| WO-2015014731-A1 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-05 | — | — | WO | claimed |
| US-20140051171-A1 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) | HOFFMANN-LA ROCHE INC. (US) | 2014-02-20 | — | — | US | claimed |
| EP-2606126-A2 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-26 | — | — | EP | claimed |
| WO-2012022725-A2 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | MMP13 706/4885MPL 511/4885ROCK2 34/4885 |
| US-20260115318-A1 | GENE CORRECTION INDUCED NEURAL STEM CELLS USING HUNTINGTIN GENE-SPECIFIC GUIDE RNA, AND CELL THERAPEUTIC AGENT USING THE SAME | HTT, NES, NSUN3 | MMP13 2314/4885MPL 3437/4885ROCK2 4418/4885 |
| US-20260132380-A1 | Hepatocyte Expansion Methods | HGF, CTNND1, MET | MMP13 558/4885MPL 1806/4885ROCK2 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.